drugset
drugset / Trial / NCT03828682

Veloxis de Novo Kidney Transplant ECSWD

NCT03828682 ↗

Phase 4 Unknown 60 enrolled Simon Tremblay, PharmD, PhD Veloxis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the safety and efficacy of LCPT in combination with rATG, mycophenolate and early corticosteroid withdrawal (CSWD) in de novo kidney transplant recipients.

Timeline

Start
2019-06-21
Primary completion
2021-07-31
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule 0.1 mg/kg Oral
Comparator Tacrolimus Small molecule 0.8 mg/kg Oral
Background Methylprednisolone Other / unclassified — Intravenous
Background Mycophenolate Mofetil Small molecule 1000 mg Oral
Background Prednisone Other / unclassified — Oral
Background Rabbit Anti-Human T-Lymphocyte Globulin Unknown 1.5 mg/kg —
Background mycophenolic acid Small molecule 720 mg Oral

Indications

immunodeficiency disease